本研究旨在证明使用 hinotori™ 手术机器人系统（Medicaroid Corporation，日本神户）进行机器人胃切除术的可行性和安全性。我们回顾性纳入了在我院使用 hinotori™ 手术机器人系统进行胃癌胃切除术的 16 例患者2023 年 6 月至 2024 年 1 月期间。控制台外科医生进行了几乎所有淋巴结切除术，包括血管夹闭术。助理外科医生使用血管封闭装置和重建期间支持淋巴结切除术。13 名患者为 cStage I，1 名患者为 cStage II，2 名患者为 cStage III。分别有 11 例、1 例和 4 例患者接受了远端胃切除术、近端胃切除术和全胃切除术。分别对 11 名和 5 名患者进行了 D1 和 D2 淋巴结切除术。分别对三名、六名、六名和一名患者进行了 Billroth-I、Billroth-II、Roux-en-Y 和食管胃造口术。中位手术时间为 282 (245-338) 分钟，中位控制台时间为 226 (185-266) 分钟。中位失血量为 28 (12-50) mL，术后第 1 天引流液中中位淀粉酶水平为 280 (148-377) U/L，术后第 3 天为 74 (42-148) U/L。一名接受近端胃切除术的患者出现吻合口瘘（Clavien-Dindo [CD] IIIa）。术后住院时间中位数为 12.5 (12-14) 天。在这个初始病例系列中，发现 hinotori™ 手术机器人系统对于胃癌患者是安全可行的，建议适合胃切除术，包括远端胃切除术和全胃切除术。© 2024 亚洲内镜外科工作组和日本内窥镜外科学会和 John Wiley

This study aims to prove the feasibility and safety of robotic gastrectomy using the hinotori™ Surgical Robot System (Medicaroid Corporation, Kobe, Japan).We retrospectively enrolled the 16 patients who underwent gastrectomy by the hinotori™ Surgical Robot System for gastric cancer at our hospital between June 2023 and January 2024. Console surgeons performed almost all lymphadenectomies, including the clipping of vessels. Assistant surgeons supported the lymphadenectomy using vessel sealing devices and during reconstruction.Thirteen patients were cStage I, one patient was cStage II, and two patients were cStage III. Distal gastrectomy, proximal gastrectomy, and total gastrectomy were performed in 11, 1, and 4 patients, respectively. D1+ and D2 lymphadenectomies were performed in 11 and 5 patients, respectively. Billroth-I, Billroth-II, Roux-en-Y, and esophagogastrostomy were performed in three, six, six, and one patients, respectively. The median operation time was 282 (245-338) min, and the median console time was 226 (185-266) min. The median blood loss was 28 (12-50) mL, and the median amylase levels in drainage fluid were 280 (148-377) U/L on postoperative day 1 and 74 (42-148) U/L on postoperative day 3. There was anastomotic leakage (Clavien-Dindo [CD] IIIa) in one patient who underwent proximal gastrectomy. The median postoperative hospital stay was 12.5 (12-14) days.In this initial case series, the hinotori™ Surgical Robot System was found to be safe and feasible for patients with gastric cancer and is suggested to be appropriate for gastrectomy, including distal gastrectomy and total gastrectomy.© 2024 Asia Endosurgery Task Force and Japan Society of Endoscopic Surgery and John Wiley & Sons Australia, Ltd.